February 6, 2018 09:37 AM EST

Array MEK/BRAF combo beats out Roche rival in PhIII melanoma OS showdown

John Carroll

Editor & Founder

Array BioPharma’s MEK/BRAF inhibitor combo handily beat out Roche’s Zelboraf on overall survival scores among a group of patients suffering from advanced melanoma with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Array MEK/BRAF combo beats out Roche rival in PhIII melanoma OS showdown

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Merck pays $30M to buy ‘chameleon’ approach to deadly brain cancers

Eye drop maker to merge with a retinal gene therapy startup from Spark co-founder

UK’s price watchdog says Lilly’s Alzheimer’s drug is too costly for broad uptake

Corrected: Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Ar­ray MEK/BRAF com­bo beats out Roche ri­val in PhI­II melanoma OS show­down

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Array MEK/BRAF combo beats out Roche rival in PhIII melanoma OS showdown